| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2018 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sale+OE | 9,000 | $92.15 | $829,358.84 | -15.5% | |
| Nov 2, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 1,500 | $97.88 | $146,820.00 | -0.5% | |
| Nov 1, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 4,000 | $92.55 | $370,200.00 | -1.4% | |
| Oct 3, 2018 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 1,000 | $98.98 | $98,984.80 | -2.0% | |
| Oct 3, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 1,500 | $99.36 | $149,040.00 | -0.5% | |
| Sep 27, 2018 | V Bryan Lawlis53 | Director | Sale+OE | 2,150 | $97.93 | $210,549.50 | -10.1% | |
| Sep 14, 2018 | George Eric Davis65 | EVP, General Counsel | Sell | 2,216 | $99.45 | $220,385.90 | -3.0% | |
| Sep 13, 2018 | George Eric Davis65 | EVP, General Counsel | Sell | 12,000 | $99.57 | $1,194,840.00 | -13.8% | |
| Sep 13, 2018 | Richard A Meier | Director | Sale+OE | 3,000 | $99.24 | $297,722.00 | -3.5% | |
| Sep 5, 2018 | Elaine J Heron | Director | Sell | 1,000 | $96.94 | $96,935.00 | -2.3% |